

Iowa Medicaid Drug Utilization Review (DUR) Commission

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 4, 2020

Location: Teleconference (Due to COVID-19)
Time: 9:30 a.m. – 1:30 p.m.

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=me7f2300a9fc5ef7a284e11ded1704691>

Dial In: 1-844-245-7693

Meeting Number: 130 919 9010

Meeting Password: CKeJRzGv322

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) August 2020 DUR Recommendation Letter to DHS
 - c) August 2020 P&T Committee Recommendation Letter
 - d) Annual DUR Commission Chairperson and Vice Chairperson Elections
 - e) Annual Completion of Conflict of Interest Disclosure
 - f) Follow-Up from Previous Meeting(s)
 - g) Commission Recommendations for Retrospective DUR Agenda Topics
 - i. Fraud, Waste, and Abuse – Suggestions from DUR Commission
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Iowa Total Care
 - b) Amerigroup
 - c) Fee-for-Service
 - d) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure.

- Written - Must submit written comments and a completed conflict of interest disclosure.
- **All submissions must be received no later than 4:30 p.m. October 28, 2020.**
- Send to info@iadur.org

6. ProDUR Edits

- a) Baclofen Quantity limits – Second Review

7. Retrospective DUR

a) Data Presentation(s)

- i. Concurrent Use of Gabapentin and Pregabalin
- ii. Concurrent Use of an SSRI and SNRI
- iii. Duplicate Therapy - Opioids

b) Proposal(s)

- i. Duplicate Therapy – Skeletal Muscle Relaxants
- ii. Concurrent Gabapentinoid and Opioid

8. Break (10 minutes)

9. Prior Authorization

a) Annual Review of Prior Authorization Criteria

- i. [PA Criteria Chart Effective November 1, 2020](#)
- ii. PA Statistics Report by Plan

b) Elagolix/Estradiol/Norethindrone Acetate (Oriahnn) – Initial Review

c) Select Anticonvulsants – Initial Review

d) Risdiplam (Evrysdi) – Initial Review

e) Satralizumab-mwge (Enspryng) – Initial Review

f) Acute Migraine Treatments – Second Review

g) Pirfenidone (Esbriet) / Nintedanib (Ofev) – Second Review

h) Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors – Second Review

i) Peanut Allergen Powder-dnfp (Palforzia) – Second Review

10. Miscellaneous

a) DUR Digest Vol. 33, No. 1 – Initial Review

b) MedWatch

[FDA warns about serious problems with high doses of the allergy medicine diphenhydramine](#)

[FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class](#)

[FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin](#)

11. Adjournment

**Next Meeting
March 3, 2021
Location TBD**

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
March 3, 2021
Location TBD